Qnexa to be Reviewed Again by FDA
A diet treatment that combines two medications some doctors already prescribe together and may lead to an increased risk of birth defects and cardiovascular problems is going to be reviewed for approval by the Food and Drug Administration, Qnexa - which is produced by Vivus and essentially consists of a combination of the stimulant phentermine and topiramate